Available compounds per May 2022
–
| Drug | Target genes |
| Abemaciclib | CCND1, CCND3, CDK4, CDK6, CCND2, CCND1 3’UTR |
| Alectinib | ALK |
| Alpelisib | PIK3CA, PIK3R1/2, PTEN, AKT, TSC1/2 |
| Atezolizumab + bevacizumab | TMB-H / HML – ≥ 16 mut/Mb |
| Axitinib | KDR, FLT4 |
| Crizotinib | ALK, MET, MST1R, ROS1 |
| Dabrafenib | BRAF V600 |
| Dabrafenib + trametinib | BRAF V600 |
| Dacomitinib | EGFR, HER2, HER4 |
| Erdafitinib | FGFR1, FGFR2, FGFR3, FGFR4 amplifications |
| Erlotinib | EGFR |
| Entrectinib | ROS1 |
| Lenvatinib | FGFR1, FGFR2, FGFR3, FGFR4 |
| Lorlatinib | ALK, ROS1 |
| Nilotinib | KIT, ABL1, PDGFRa, PDGFRb |
| Nivolumab | MSI-H |
| Nivolumab + ipilimumab | HML: > 199 and < 1000 TMB-H: 15 – 39 (TSO500) or 11 – 24 (Oncomine pane) |
| Olaparib | ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD54L |
| Panitumumab | RAF/RAS wildtype |
| Pembrolizumab | HML |
| Regorafenib | RET, KIT, FLT1, BRAF |
| Rucaparib | BRCA1, BRCA2, RAD51C, RAD51D, PALB2 |
| Sunitinib | CSF1R, FGFR1, FGFR2, FGFR3, FLT3, KDR, FLT4, KIT, PDGFRa, PDGFRb, RET |
| Talazoparib | ATM, ATR, FANCA, FANCC, FANCD2, FANCF, FANCM, RAD51, RAD51B, RAD54L, NBN, MRE11, BARD1, BRIP1, CHEK1, CHEK2, PALB2, PRA1, HRD signature |
| Trametinib | MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K4, MAP3K1, NRAS, GNA11, GNAQ, GNAS, BRAF, NF1 (only gliomas) |
| Trastuzumab + pertuzumab | HER2 |
| Vemurafenib + cobimetinib | BRAF |
| Vismodegib | PTCH1 |
| Drug | Tumor type | Target | Status |
| Abemaciclib | Esophageal | CCND3 amp | Open |
| Abemaciclib | Glioblastoma | CDK4 amp | Open |
| Abemaciclib | HNSCC | CCND1 amp | Open |
| Abemaciclib | Melanoma | CCND1 amp | Open |
| Abemaciclib | NSCLC | CCND1 amp | Open |
| Abemaciclib | Ovarian | CCND1 amp | Open |
| Abemaciclib | Prostate | CCND1 amp | Open |
| Abemaciclib | Sarcoma | CDK4 amp | Open |
| Abemaciclib | SCC bladder | CCND1 amp | Open |
| Abemaciclib | Urachal cancer | CCND1 amp | Open |
| Abemaciclib | Carcinoma of the small intestine | CCND3amp | Open |
| Abemaciclib | Carcinoma of the small intestine | CDK4 amp | Open |
| Abemaciclib | Urinary tract | CCND1 amp | Open |
| Afatinib | NSCLC | NRG1 fusion | Closed |
| Alectinib | Tumor-agnostic | ALK fusion | Open |
| Alectinib | Tumor-agnostic | ALK mut/amp | Open |
| Alpelisib | Tumor-agnostic | Double hit | Open |
| Alpelisib | Anal cancer | PIK3R2 mut | Open |
| Alpelisib | Gynaecological tumors | AKT1 mut | Open |
| Alpelisib | Gynaecological tumors | PTEN loss | Open |
| Alpelisib | Gynaecological tumors | PIK3R1 mut | Open |
| Alpelisib | Gynaecological SCC | PIK3CA mut | Open |
| Alpelisib | Gynaecological PCC | PIK3CA mut | Open |
| Alpelisib | HNSCC | PIK3Ca mut | Open |
| Alpelisib | Miscellaneous tumors | PIK3CA mut | Open |
| Alpelisib | NEC cervical | PTEN loss | Open |
| Alpelisib | Prostate | PIK3CA mut | Open |
| Alpelisib | Prostate | PTEN loss | Open |
| Alpelisib | Renal cell | PTEN loss | Open |
| Alpelisib | Salivary gland | PTEN loss | Open |
| Alpelisib | Upper-GI | PIK3CA mut | Open |
| Alpelisib | Folliculair schildkliercarcinoom | PTEN loss | Open |
| Atezolizumab + bevacizumab | Tumor-agnostic | TMB ≥16 mut/Mb | Open |
| Axitinib | CRC | FLT1 amp | Closed |
| Cabozantinib | Esophageal | MET mut | Closed |
| Cabozantinib | GIST | NTRK2 mut | Closed |
| Cabozantinib | Melanoma | MET amp | Closed |
| Cabozantinib | NSCLC | Ret fusion | Closed |
| Cabozantinib | Esophageal | RET mut | Closed |
| Cabozantinib | NSCLC | MET mut | Closed |
| Cabozantinib | Teratoma | MET amp | Closed |
| Crizotinib | ACUP | ALK fusion | Open |
| Crizotinib | Biliary tract | ALK mut | Open |
| Crizotinib | Colorectal | ALK mut | Open |
| Crizotinib | Colorectal | MET amp | Open |
| Crizotinib | Esophageal | MET amp | Open |
| Crizotinib | Gastric | MET amp | Open |
| Crizotinib | Inflammatory myofibrlastic tumor | ALK fusion | Open |
| Crizotinib | Hepatocellular | MET amp | Open |
| Crizotinib | NSCLC | MET amp | Open |
| Crizotinib | NSCLC | MET mut | On hold |
| Crizotinib | T cell lymphoma | ALK mut | Open |
| Crizotinib | Thyroid | ALK mut | Open |
| Crizotinib | Thyroid | MET fusion | Open |
| Crizotinib | Ovarian | MET amp | Open |
| Crizotinib | Sarcoma | ALK | Open |
| Crizotinib | Renal cell | MET mut | Open |
| Dabrafenib | Glioblastoma | BRAF V600 mut | Open |
| Dabrafenib | Urinary tract | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Biliary tract | BRAF V600 mut | Open |
| Dabrafenib + trametinib | GIST | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Glioblastoma | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Glioma (grade 3) | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Low grade glioma | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Mamma | BRAF V600 mut | Open |
| Dabrafenib + trametinib | Neuroendocrine carcinoma colon | BRAF V600 mut | Open |
| Dabrafenib + trametinib | NSCLC | BRAF V600 mut | Closed |
| Dacomitinib | Breast | HER2 mut | Open |
| Dacomitinib | Cervix | HER2 mut | Open |
| Dacomitinib | Colorectal | EGFR amp | Open |
| Dacomitinib | Colorectal | HER2 amp | Open |
| Dacomitinib | Endometrial | HER2 amp | Open |
| Dacomitinib | Endometrial | HER2 mut | Open |
| Dacomitinib | Esophageal | HER2 amp | Open |
| Dacomitinib | Gastro-esophageal junction | HER2 amp | Open |
| Dacomitinib | Penile | HER2 fusion | Open |
| Dacomitinib | Penile | EGFR amp | Open |
| Dacomitinib | Urinary tract | EGFR amp | Open |
| Durvalumab | Tumor-agnostic | MSI | Closed |
| Erdafitinib | Breast | FGFR1amp | Open |
| Erlotinib | CRC | EGFR mut | Open |
| Erlotinib | GBM | EGFR fusion | Open |
| Erlotinib | GBM | EGFR mut | Open |
| Lenvatinib | Adenoid cystic carcinoma | FGFR2 mut | Open |
| Lenvatinib | ACUP | FGFR2 fusion | Open |
| Lenvatinib | Anal cancer | FGFR3 mut | Open |
| Lenvatinib | Anaplastic thyroid | FGFR3 mut | Open |
| Lenvatinib | Biliary tract | FGFR2 fusion | Open |
| Lenvatinib | Biliary tract | FGFR3 fusion | Open |
| Lenvatinib | Biliary tract | FGFR2 mut | Open |
| Lenvatinib | Biliary tract | FGFR3 mut | Open |
| Lenvatinib | Cervix | FGFR3 mut | Open |
| Lenvatinib | Colorectal | FGFR1 amp | Open |
| Lenvatinib | Colorectal | FGFR2 amp | Open |
| Lenvatinib | Endometrium | FGFR2 mut | Open |
| Lenvatinib | Endometrium | FGFR3 amp | Open |
| Lenvatinib | Esophageal | FGFR2 amp | Open |
| Lenvatinib | Glioblastoma | FGFR3 fusion | Open |
| Lenvatinib | Glioneural tumor | FGFR1 mut | Open |
| Lenvatinib | Glioma | FGFR1 mut | Open |
| Lenvatinib | HNSCC | FGFR3 mut | Open |
| Lenvatinib | Mamma | FGFR1 amp | Open |
| Lenvatinib | Mamma | FGFR2 amp/mut | Open |
| Lenvatinib | Neuroendocrine nasal cavity | FGFR3 amp | Open |
| Lenvatinib | NSCLC | FGFR1 amp | Open |
| Lenvatinib | NSCLC | FGFR2 amp | Open |
| Lenvatinib | NSCLC | FGFR3 fusion | Open |
| Lenvatinib | Osteosarcoma | FGFR1 amp | Open |
| Lenvatinib | Pancreas | FGFR1 amp | Open |
| Lenvatinib | Pancreas | FGFR2 fusion | Open |
| Lenvatinib | Papillary cancer | FGFR2 mut | Open |
| Lenvatinib | Salivary gland | FGFR3 amp | Open |
| Lenvatinib | Salivary duct | FGFR2 mut | Open |
| Lenvatinib | Urachal cancer | FGFR2 amp | Open |
| Lenvatinib | Urinary tract | FGFR3 mut | Open |
| Lenvatinib | Vagina | FGFR3 mut | Open |
| Lorlatinib | NSCLC | ROS1 fusion | Open |
| Nilotinib | Colorectal | PDGFRB amp | Open |
| Nilotinib | Germ cell | KIT mut | Open |
| Nilotinib | GIST | KIT mut | Open |
| Nilotinib | GIST | PDGFRA mut | Open |
| Nilotinib | Melanoma | KIT mut | Open |
| Nilotinib | Mesothelioma | PDGFRA mut | Open |
| Nivolumab | Tumor-agnostic | MSI (2nd stage) | Closed |
| Nivolumab | Tumor-agnostic | MSI (3rd stage) | On hold |
| Nivolumab | Tumor-agnostic | HML >450 | Closed |
| Nivolumab + ipilimumab | Tumor-agnostic | HML 200-1000 | Open |
| Olaparib | Tumor-agnostic | BRCA mut/loss | Closed |
| Olaparib | Tumor-agnostic | ATM mut/loss | Open |
| Olaparib | Tumor-agnostic | HRR alterations (breast, ovarian, prostate, pancreas, SCLC or stomach carcinoma) | Open |
| Olaparib | Tumor-agnostic | HRR alterations (all other tumor types) | Open |
| Panitumumab | ACUP | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Anal cancer | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Cervix | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Endometrium | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Glioblastoma | BRAF-KRAS-NRAS wildtype | On hold |
| Panitumumab | Gynaecological SCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | HNSCC | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Meningioma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | (uvual) melanoma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | NSCLC | BRAF-KRAS-NRAS wildtype + EGFR mut/amp | Open |
| Panitumumab | Salivary duct | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Sarcoma | BRAF-KRAS-NRAS wildtype | Open |
| Panitumumab | Thyroid | BRAF-KRAS-NRAS wildtype | Open |
| Palbociclib | Astrocytoma | CDK4 amp | Closed |
| Palbociclib | Biliary tract | CDKN2A loss/mut | Closed |
| Palbociclib | Colorectal | CCND2 amp | Closed |
| Palbociclib | Colorectal | CDKN2A loss/mut | Closed |
| Palbociclib | Colorectal | SMARCA4 mut | Closed |
| Palbociclib | Duodenal | CDKN2A loss/mut | Closed |
| Palbociclib | Endometrial carcinoma | CDKN2A loss/mut | Closed |
| Palbociclib | Esophageal | CDK4 amp | Closed |
| Palbociclib | Esophageal | CDKN2A loss/mut | Closed |
| Palbociclib | Glioblastoma | CDKN2A loss/mut | Closed |
| Palbociclib | HNSCC | CDKN2A loss/mut | Closed |
| Palbociclib | Melanoma | CCND1 amp | Closed |
| Palbociclib | Melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | Neuroendocrine tumor | CDKN2A loss/mut | Closed |
| Palbociclib | Neuroendocrine tumor | CCND1 amp | Closed |
| Palbociclib | NSCLC | CCND1 amp | Closed |
| Palbociclib | NSCLC | CDKN2A loss/mut | Closed |
| Palbociclib | (uvual) melanoma | CDKN2A loss/mut | Closed |
| Palbociclib | Ovarian | CDKN2A loss/mut | Closed |
| Palbociclib | Ovarian | SMARCA4 mut | Closed |
| Palbociclib | Pancreas | CDKN2A loss/mut | Closed |
| Palbociclib | PECoom | CDK4 amp | Closed |
| Palbociclib | Primitive Neuro-ectodermal tumor | CDKN2A loss/mut | Closed |
| Palbociclib | Prostate | CDK4 amp | Closed |
| Palbociclib | Prostate | CDK6 amp | Closed |
| Palbociclib | Renal cell | CDKN2A loss/mut | Closed |
| Palbociclib | Sarcoma | CDK4 amp | Closed |
| Palbociclib | Vulva carcinoma | CDKN2A loss/mut | Closed |
| Palbociclib | Vulva carcinoma | CCND1 amp | Closed |
| Pembrolizumab | Colorectal | HML 140-290 | Closed |
| Pembrolizumab | HNSCC | HML 140-290 | Open |
| Pembrolizumab | Mamma | HML 140-290 | Closed |
| Pembrolizumab | Miscellaneous tumors | HML 140-290 | Closed |
| Pembrolizumab | Prostate | HML 140-290 | Open |
| Pembrolizumab | Upper-GI | HML 140-290 | Closed |
| Pembrolizumab | Tumor-agnostic | HML > 290 | Closed |
| Regorafenib | Adenoid cystic carcinoma | BRAF mut | Open |
| Regorafenib | Duodenal | FLT1 amp | Open |
| Regorafenib | Melanoma | KIT mut | Open |
| Regorafenib | Esthesioneuroblastoma | RET | Open |
| Regorafenib | NSCLC | RAF1 mut | Open |
| Regorafenib | NSCLC | RET | Open |
| Regorafenib | Thymus | KIT mut | Open |
| Ribociclib | Anaplastic meningeoma | CDKN2A loss/mut | Closed |
| Ribociclib | ACUP | CDKN2A loss/mut | Closed |
| Ribociclib | Ceruminous adenocarcinoma | CDKN2A loss/mut | Closed |
| Ribociclib | Ependymoma | CDKN2A loss/mut | Closed |
| Ribociclib | Gastric cancer | CDKN2A loss/mut | Closed |
| Ribociclib | Melanoma | CDK4 amp | Closed |
| Ribociclib | Mesothelioma | CDKN2A loss/mut | Closed |
| Ribociclib | Mucoepidermoid | CDK6 amp | Closed |
| Ribociclib | Prostate | CDKN2A loss/mut | Closed |
| Ribociclib | Salivary gland | CDKN2A loss/mut | Closed |
| Ribociclib | Sarcoma | CDKN2A loss/mut | Closed |
| Ribociclib | Thymus | CDKN2A loss/mut | Closed |
| Ribociclib | Urinary tract | CDKN2A loss/mut | Closed |
| Rucaparib | Mamma | HRR alterations | Open |
| Rucaparib | Miscellaneous tumors | HRR alterations | Open |
| Rucaparib | Ovarian | HRR alterations | Open |
| Rucaparib | Pancreas | HRR alterations | Open |
| Rucaparib | Prostate | HRR alterations | Open |
| Sunitinib | Adenoid cystic carcinoma | PDGFRA amp | Open |
| Sunitinib | Colorectal | CSF1R mut | Open |
| Sunitinib | Colorectal | FLT3 mut | Open |
| Sunitinib | Colorectal | FLT3 amp | Open |
| Sunitinib | Mamma | PDGFRB amp | Open |
| Sunitinib | NSCLC | KIT amp | Open |
| Sunitinib | Osteosarcoma | PDFGRB mut | Open |
| Sunitinib | Ovarian | FGFR1 amp | Open |
| Sunitinib | Ovarian | FGFR2 amp | Open |
| Sunitinib | Pancreas | RET fusion | Open |
| Sunitinib | Pseudomyxoma peritonei | FLT3 mut | Open |
| Sunitinib | Prostate | PDFGRA mut | Open |
| Sunitinib | Thymus | KIT mut | Open |
| Sunitinib | Thyroid cancer | PDGFRA mut | Open |
| Sunitinib | Urinary tract | FGFR1 amp | Open |
| Talazoparib | Tumor-agnostic | ATM/ATR alteraties | Open |
| Talazoparib | Tumor-agnostic | HRD signature | Open |
| Trametinib | ACUP | MAP2K1 mut | Open |
| Trametinib | ACUP | MAP3K1mut | Closed |
| Trametinib | Cervix | MAP3K1mut | Closed |
| Trametinib | Cholangiocarcinoma | MAP2K4 mut | Closed |
| Trametinib | Cholangiocarcinoma | NRASmut | Open |
| Trametinib | Colorectal | MAP2K4 mut | Closed |
| Trametinib | Colorectal | MAP2K1 mut | Open |
| Trametinib | Glioneural tumor | BRAF fusion | Open |
| Trametinib | Histiocytair sarcoma | MAP2K1mut | Open |
| Trametinib | Mamma | MAP3K1 mut | Closed |
| Trametinib | Mamma | MAP2K4 mut | Closed |
| Trametinib | Melanocytic tumor | GNA11 mut | Open |
| Trametinib | Neuroendocrine carcinoma | MAP3K1 mut | Closed |
| Trametinib | NSCLC | BRAF mut | Open |
| Trametinib | NSCLC | BRAF fusion | Open |
| Trametinib | NSCLC | MAP2K1 mut | Open |
| Trametinib | NSCLC | NRAS mut | Open |
| Trametinib | Ovarian | MAP2K4 mut | Closed |
| Trametinib | Ovarian | NRAS mut | Open |
| Trametinib | Pancreas | BRAF fusie | Open |
| Trametinib | Pancreas | MAP2K1 mut | Open |
| Trametinib | Pancreas | MAP2K4 mut | Closed |
| Trametinib | (Pilocytic) astrocytoma | BRAF fusion | Open |
| Trametinib | Pleimorph tumor | NRAS mut | Open |
| Trametinib | Prostate | MAP3K1 mut | Closed |
| Trametinib | Prostate | NRAS mut | Open |
| Trametinib | Salivary duct | BRAF fusion | Open |
| Trametinib | Salivary duct | NRAS mut | Open |
| Trametinib | Stomach cancer | MAP2K1 mut | Open |
| Trametinib | Thyroid | NRAs mut | Open |
| Trametinib | All tumor types | GNAS mut | Open |
| Trametinib | All tumor types | NF1 mut | Open |
| Trametinib | Urinary tract | BRAF fusion | Open |
| Trametinib | Yolk sac tumor | NRAS mut | Open |
| Trastuzumab + pertuzumab | Adenoid cystic carcinoma | HER2 mut | Open |
| Trastuzumab + pertuzumab | Biliary tract | HER2 amp | Open |
| Trastuzumab + pertuzumab | Cervix | HER2 amp | Open |
| Trastuzumab + pertuzumab | Cervix | HER2 mut | Open |
| Trastuzumab + pertuzumab | Colorectal | HER2 amp | Open |
| Trastuzumab + pertuzumab | Colorectal | HER2 mut | Open |
| Trastuzumab + pertuzumab | Duodenal | HER2 amp | Open |
| Trastuzumab + pertuzumab | Hidradenocarcinoma | HER2 amp | Open |
| Trastuzumab + pertuzumab | Melanoma | HER2 amp | Open |
| Trastuzumab + pertuzumab | Neuroendocrine carcinoma | HER2 amp | Open |
| Trastuzumab + pertuzumab | NSCLC | HER2 amp | Open |
| Trastuzumab + pertuzumab | NSCLC | HER2 mut | Closed |
| Trastuzumab + pertuzumab | Ovarian | HER2 amp | Open |
| Trastuzumab + pertuzumab | Ovarian | HER2 mut | Open |
| Trastuzumab + pertuzumab | Salivary duct | HER2 amp | Open |
| Trastuzumab + pertuzumab | Sinosal carcinoma | HER2 mut | Open |
| Trastuzumab + pertuzumab | Urinary tract | HER2 amp | Open |
| Trastuzumab + pertuzumab | Urinary tract | HER2 mut | Open |
| Trastuzumab + pertuzumab | Vulva | HER2 amp | Open |
| Vemurafenib + cobimetinib | ACUP | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Erdheim Chester Disease | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | NSCLC | BRAF V600E mut NSCLC | Open |
| Vemurafenib + cobimetinib | NSCLC | BRAF non-V600 mut | Open |
| Vemurafenib + cobimetinib | Papillair craniopharyngeoma | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Prostate | BRAF non-V600 mut | Open |
| Vemurafenib + cobimetinib | Thyroid | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Ovarian | BRAF V600 mut | Open |
| Vemurafenib + cobimetinib | Salivary duct | BRAF V600 mut | Open |
| Vismodegib | Sarcoma | PTCH1 mut | Open |
| Vismodegib | CNS tumors | PTCH1 mut | Open |